Related Experiment Video
Updated: Jun 17, 2026

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
Published on: July 29, 2016
Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2
Anna Vihola1, Linda L Bachinski, Mario Sirito
1Department of Medical Genetics, Folkhälsan Institute of Genetics, University of Helsinki, 00014 Helsinki, Finland.
Abstract:
Aberrant transcription and mRNA processing of multiple genes due to RNA-mediated toxic gain-of-function has been suggested to cause the complex phenotype in myotonic dystrophies type 1 and 2 (DM1 and DM2). However, the molecular basis of muscle weakness and wasting and the different pattern of muscle involvement in DM1 and DM2 are not well understood. We have analyzed the mRNA expression of genes encoding muscle-specific proteins and transcription factors by microarray profiling and studied selected genes for abnormal splicing. A subset of the abnormally regulated genes was further analyzed at the protein level. TNNT3 and LDB3 showed abnormal splicing with significant differences in proportions between DM2 and DM1. The differential abnormal splicing patterns for TNNT3 and LDB3 appeared more pronounced in DM2 relative to DM1 and are among the first molecular differences reported between the two diseases. In addition to these specific differences, the majority of the analyzed genes showed an overall increased expression at the mRNA level. In particular, there was a more global abnormality of all different myosin isoforms in both DM1 and DM2 with increased transcript levels and a differential pattern of protein expression. Atrophic fibers in DM2 patients expressed only the fast myosin isoform, while in DM1 patients they co-expressed fast and slow isoforms. However, there was no increase of total myosin protein levels, suggesting that aberrant protein translation and/or turnover may also be involved.
Insights
Myotonic dystrophies type 1 and 2 (DM1 and DM2) show distinct molecular differences in gene splicing and myosin expression, impacting muscle function. These findings offer new insights into the varying muscle involvement in DM1 and DM2.
Area of Science:
- Molecular Biology
- Genetics
- Neuromuscular Disorders
Background:
- Myotonic dystrophies type 1 (DM1) and type 2 (DM2) share complex phenotypes, but the precise molecular basis for muscle weakness and differential muscle involvement remains unclear.
- RNA-mediated toxic gain-of-function is implicated in DM1 and DM2 pathogenesis, affecting gene transcription and mRNA processing.
Purpose of the Study:
- To investigate the molecular differences in gene expression and splicing between DM1 and DM2.
- To elucidate the molecular basis of muscle weakness and differential muscle involvement in DM1 and DM2.
Main Methods:
- Microarray profiling of mRNA expression for muscle-specific genes and transcription factors.
- Analysis of abnormal splicing in selected genes.
- Protein level analysis of abnormally regulated genes.
Main Results:
- Differential abnormal splicing of TNNT3 and LDB3 genes observed, with more pronounced patterns in DM2 compared to DM1.
- Global abnormalities in myosin isoforms, including increased transcript levels in both DM1 and DM2.
- Distinct myosin isoform expression in atrophic muscle fibers: DM2 exclusively fast myosin, DM1 co-expression of fast and slow myosin.
Conclusions:
- Abnormal splicing of TNNT3 and LDB3 represents a key molecular distinction between DM1 and DM2.
- Differential myosin isoform expression in atrophic fibers contributes to the distinct muscle pathology in DM1 and DM2.
- Aberrant protein translation and/or turnover may also play a role in the pathogenesis of myotonic dystrophies.
Related Concept Videos
Satellite Stem Cells and Muscular Dystrophy
Alterations in Muscle Tone lll
RNA Splicing
The Sarcomere
Each myosin...
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy

